Results 161 to 170 of about 38,893 (219)

Identifying opioid agonist treatment prescriber networks from health administrative data: A validation study. [PDF]

PLoS One
Kurz M, Tatangelo M, Morin KA, Zanette M, Krebs E, Marsh DC, Nosyk B.   +6 more
europepmc   +1 more source

Initiation of High‐Potency Benzodiazepine Prescriptions Among Survivors of Severe Trauma

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 6, July 2026.
ABSTRACT Background Trauma is a major public health concern that often leads to long‐term psychological distress and chronic pain. Benzodiazepines (BZDs) are sometimes prescribed for anxiety, insomnia, or acute stress‐related symptoms, but long‐term use is associated with dependence and adverse outcomes.
Anders Oldner, Mikael Eriksson, Emma Larsson, Jesper Eriksson, Erik von Oelreich   +4 more
wiley   +1 more source

Cohort profile: the provincial opioid agonist treatment cohort in Ontario, Canada. [PDF]

Eur J Epidemiol
Morin KA, Tatangelo MR, Acharya S, Marsh DC.   +3 more
europepmc   +1 more source

Testosterone Versus Clomiphene Treatment of Hypogonadism: A Retrospective Analysis in US Veterans

Andrology, Volume 14, Issue 5, Page 1292-1299, July 2026.
ABSTRACT Background Male hypogonadotropic hypogonadism is a complex condition with a multifactorial etiology. Although testosterone replacement therapy (TRT) is the only approved treatment for male hypogonadism, clomiphene citrate (CC) is often used as an off‐label treatment.
Shourya Tadisina, Elizabeth Cristiano, Thomas Wiegmann, Ken Grasing, Betty Drees, Ram Sharma, Mariana Garcia‐Touza   +6 more
wiley   +1 more source

Initiation of opioid agonist treatment following hospital-treated opioid toxicities and the risk of repeat events in Ontario, Canada: a cohort study using inverse probability of treatment weights. [PDF]

BMJ Public Health
Ledlie S, Tadrous M, Bayoumi AM, McCormack D, Kent JT, Besharah J, Munro C, Gomes T.   +7 more
europepmc   +1 more source

The Effect of Dopaminergic Medication on Impulse Control and Compulsive Behaviour: A Translational Perspective

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 1, July 2026.
ABSTRACT Dopaminergic medication used in disorders like Parkinson's disease (PD) and restless legs syndrome can cause impulsive‐compulsive behaviour (ICB), often with strong negative effects on patients' quality of life. This narrative review presents translational evidence on iatrogenic ICB, taking findings from epidemiological, clinical, neuroimaging
Mirjam Wolfschlag, Elena Espa, Kevin Oliveira Hauer, Jonathan Timpka, Ruben Smith, Per Odin, Maria Angela Cenci, Anders Håkansson   +7 more
wiley   +1 more source

Exploring the early impacts of drug decriminalization on harm reduction and opioid agonist treatment service operations and delivery in British Columbia: insights from key informant interviews. [PDF]

BMC Public Health
Russell C, Torres-Salbach S, MacKinnon L, Shahin R, Griffith D, Hodgson K, Burmeister C, Amoraal C, Crichlow F, Imtiaz S, Rehm J, Ali F.   +11 more
europepmc   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, Volume 183, Issue 14, Page 3970-3991, July 2026.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

The impact of opioid agonist treatment on the incidence of bacterial sexually transmitted infection notifications among people with a history of opioid dependence in New South Wales, Australia: A retrospective data linkage study. [PDF]

Drug Alcohol Depend
Price O, Bharat C, Jones NR, Peacock A, Read P, Hickman M, Degenhardt L.   +6 more
europepmc   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, Volume 183, Issue 14, Page 3992-4005, July 2026.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source